PF-Atlas › Clinical Trials › NCT00109681

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

Iloprost Inhalation Solution · Phase 2

Registry ID
NCT00109681
Phase
Phase 2
Status
Completed
Drug / intervention
Iloprost Inhalation Solution (Ventavis)
Sponsor
Actelion
Start
2005-04
Enrollment
50
Locations
17

About this trial

The primary purpose of this study is to determine whether iloprost inhalation solution is safe in subjects with idiopathic pulmonary fibrosis (IPF) and elevated pulmonary arterial pressure. The secondary purpose is to evaluate the effectiveness of this treatment in subjects with this disease.

View NCT00109681 on ClinicalTrials.gov →

Explore related

All Iloprost Inhalation Solution trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00109681 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.